Author + information
To observe the efficacy and safety of levosimendan in the treatment of heart failure based on conventional anti-heart failure therapy and renal protection therapy in patients with heart failure complicated with renal insufficiency.
There were all 62 cases of heart failure with renal insufficiency patients whom were hospitalized in Department of Congenital Cardiology, General Hospital of Shenyang Military Area Command during November 2012 and December 2015. They were 33 cases of male patients, 29 cases of female patients. They were randomly divided into control group(31cases) and treatment group(31cases). Control group was given conventional therapy and dobutamine therapy(the concentration of 3ug / kg / min continuous intravenous infusion of 10h, 1 / d, once every 7 days). The treatment group received both conventional therapy and levosimendan therapy(using levosimendan 6ug / kg + 5% glucose 20ml, 10min static push, and then 0.1ug / kg / min concentration of continuous intravenous pump 24h). Serum creatinine, creatinine clearance, N-terminal pro-brain natriuretic peptide (NT-ProBNP) and left ventricular ejection fraction (LVEF) were recorded at medication the same day, 24, 72 and 1 week after drug administration.
Cardiac function and renal function were improved in both groups. Creatinine clearance rate, NT-ProBNP decreased compared with before treatment. However, compared with the control group, the increase of creatinine clearance rate and the decrease of NT-ProBNP in the test group were more obvious (P <0.05), and the patients had no obvious adverse reactions during the treatment.
Severe heart failure with renal dysfunction in patients on the basis of conventional treatment plus levosimendan, for patients with heart and kidney function improvement is safe and effective.